Patents Assigned to Glenmark Generics Ltd.
-
Patent number: 8937188Abstract: A solid crystalline form of 1-(2-[4-(6-methoxy-3,4-dihydronaphthalene-1-y) phenoxy]ethyl)pyrrolidine, and a preparing process thereof are provided. The aforesaid compound is a key intermediate in the synthesis of lasofoxifene. A process for preparing lasofoxifene, a process for purifying lasofoxifene tartrate, and a crystalline form of lasofoxifene tartrate are also provided.Type: GrantFiled: April 27, 2010Date of Patent: January 20, 2015Assignee: Glenmark Generics Ltd.Inventors: Mubeen Ahmed Khan, Nikhil Rasiklal Trivedi, Nagan Nirmalan Kandasamy, Dayaghan Gangadhar Patil, Vipin Kumar Pandey, Sukumar Sinha
-
Publication number: 20140072628Abstract: Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer.Type: ApplicationFiled: September 11, 2013Publication date: March 13, 2014Applicant: Glenmark Generics Ltd.Inventors: Atul Kaushik, Arra Ganga Srinivas, Kamal Mehta
-
Patent number: 8624041Abstract: A process for the preparation of strontium ranelate or a hydrate thereof is provided comprising (a) reacting a tetraester compound of Formula II: wherein R, R1, R2, and R3 are independently a linear or branched C1-C6 alkyl group or a substituted or unsubstituted C3-C12 cyclic group, in the presence of a lithium base and in a solvent with an inorganic acid salt of strontium.Type: GrantFiled: August 18, 2006Date of Patent: January 7, 2014Assignee: Glenmark Generics Ltd.Inventors: Bobba Venkata Siva Kumar, Kosampally Srinivas, Sanjay Anantha Kale, Nitin Sharad Chandra Pradhan
-
Patent number: 8450376Abstract: The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.Type: GrantFiled: June 15, 2009Date of Patent: May 28, 2013Assignee: Glenmark Generics Ltd.Inventors: Shankar Sanganabhatla, Vijay Soni, Mubeen Ahmed Khan, Nandlal Agarwal, Hemanth Kamble, Sharad Gore
-
Publication number: 20120028045Abstract: The present invention relates to processes for the preparation of indiplon and its polymorphic mixtures.Type: ApplicationFiled: March 18, 2010Publication date: February 2, 2012Applicant: Glenmark Generics LTDInventors: Joseph Prabahar Koilpillai, Sanjay Anantha Kale, Laxmikant Madhukar Kelkar, Sunil Sudhakar Zope, Mubeen Ahmed Khan
-
Publication number: 20120022047Abstract: The present invention relates to the purification and particle size of eslicarbazepine acetate. The present invention also relates to the physical characteristics of solid state eslicarbazepine acetate, and pharmaceutical compositions containing the same.Type: ApplicationFiled: March 30, 2010Publication date: January 26, 2012Applicant: GLENMARK GENERICS LTDInventors: Joseph Prabahar Koilpillai, Pravin Bhalchandra Kulkarni, Sachin Bapurao Sawant, Nagesh Devidasrao Limbekar
-
Patent number: 8097729Abstract: Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.Type: GrantFiled: September 18, 2006Date of Patent: January 17, 2012Assignee: Glenmark Generics Ltd.Inventors: Mangesh Shivram Sawant, Maloyesh Mathuresh Biswas, Mubeen Ahmed Khan, Sukumar Sinha, Nitin Sharad Chandra Pradhan
-
Publication number: 20110281928Abstract: The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.Type: ApplicationFiled: January 24, 2010Publication date: November 17, 2011Applicant: GLENMARK GENERICS LTDInventors: Mubeen Ahmed Khan, Roop Singh Yadav, Nikhil Rasiklal Trivedi, Sachin Mahedo Lad
-
Publication number: 20110207779Abstract: The present invention relates to a process for the preparation of esomeprazole magnesium containing R-isomer greater than about 0.1% by wt. In particular, the present invention relates to a process for the preparation of esomeprazole magnesium dihydrate containing R-isomer greater than about 0.1% by wt.Type: ApplicationFiled: April 28, 2010Publication date: August 25, 2011Applicant: GLENMARK GENERICS LTDInventors: Koilpillai Joseph Prabahar, Veerabhadra Swamy Hiremath, Milind Moreshwar Gharpure, Nagan Nirmalan Kandaswamy, Avekumar Digambar Dabe, Kamal Mehta, Pankajkumar Shinde
-
Publication number: 20110105619Abstract: The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.Type: ApplicationFiled: June 15, 2009Publication date: May 5, 2011Applicant: Glenmark Generics Ltd.Inventors: Shankar Sanganabhatla, Vijay Soni, Mubeen Ahmed Khan, Nandlal Agarwal, Hemanth Kamble, Sharad Gore
-
Publication number: 20110053898Abstract: A topical pharmaceutical composition comprising therapeutically effective amounts of vitamin D or vitamin D analogues, corticosteroid and a straight chain C6-C28 fatty alcohol.Type: ApplicationFiled: August 24, 2010Publication date: March 3, 2011Applicant: GLENMARK GENERICS LTDInventors: Kamal Mehta, Amol Mandhare, Shantesh Patil, Tapan Nayak, Lalatendu Panigrahi
-
Publication number: 20110052687Abstract: The present invention provides an extended release tablet of paliperidone, comprising a) a core containing paliperidone and at least one water soluble and/or gellable polymer, b) a coating comprising at least one water insoluble or permeable polymer, and a water soluble and/or gellable polymer and optionally an enteric polymer.Type: ApplicationFiled: August 25, 2010Publication date: March 3, 2011Applicant: GLENMARK GENERICS LTDInventors: Kamal Mehta, Pankaj Shinde, Hidaytulla Aga, Rajadeep Gupta
-
Publication number: 20110038928Abstract: The present invention is directed to a novel rapidly dissolvable pharmaceutical composition comprising zolmitriptan or pharmaceutically acceptable salts or esters thereof and least one direct compression filler. The pharmaceutical compositions of the present invention can advantageously be prepared in a solid dosage form, e.g. a tablet, utilizing directly compressible ingredients.Type: ApplicationFiled: August 10, 2010Publication date: February 17, 2011Applicant: GLENMARK GENERICS LTDInventors: Kamal Mehta, Srinivas Ganga Arra, Chandramala A. Kaushal, Manish Maheshwari
-
Patent number: 7863273Abstract: A substantially pure dextrorotatory isomer of zopiclone or a pharmaceutically acceptable salt thereof and crystalline forms thereof are provided. Also provided is a process for its preparation and pharmaceutical compositions containing same.Type: GrantFiled: December 29, 2006Date of Patent: January 4, 2011Assignee: Glenmark Generics Ltd.Inventors: Biju Kumar Gopinathen Pillai, Sankar Arjunan, Nitin Sharad Chandra Pradhan, Narendra Shriram Joshi
-
Publication number: 20100317856Abstract: The present invention provides processes for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 27, 2008Publication date: December 16, 2010Applicant: GLENMARK GENERICS LTDInventor: SANKAR ARJUNAN
-
Publication number: 20100310870Abstract: The present invention relates to amorphous form of bazedoxifene acetate and a process for the preparation thereof.Type: ApplicationFiled: March 16, 2010Publication date: December 9, 2010Applicant: GLENMARK GENERICS LTD.Inventors: Shankar Sanganabhatla, Sachin Srivastava, Dinesh Bansilal Deore, Anthony Melvin Crasto, Mubeen Ahmed Khan
-
Publication number: 20100292267Abstract: The present invention provides novel palonosetron free base in an amorphous form and crystalline form-G and processes for their preparation. The present invention also provides a process for the preparation of palonosetron hydrochloride from the novel palonosetron free base in an amorphous form and/or in crystalline form-G.Type: ApplicationFiled: December 11, 2008Publication date: November 18, 2010Applicant: GLENMARK GENERICS LTDInventors: Mubeen Khan, Mahendra Patil Raghunath, Prashant Yadav Kundlik
-
Publication number: 20100068284Abstract: The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.Type: ApplicationFiled: March 16, 2009Publication date: March 18, 2010Applicant: GLENMARK GENERICS LTDInventors: Ulhas Rameshchandra Dhuppad, Nitin Babulal Bhamre, Sunil Sudhakar Chaudhari, Girish Trivedi, Akhilesh Dayanand Sharma, Prashant Dongre
-
Publication number: 20100028425Abstract: The present invention relates to immediate release pharmaceutical compositions for oral administration comprising micronized atovaquone particles and at least one drug, wherein about 90% of the atovaquone particles have a volume diameter between about 4 ?m to about 8 ?m; and having a uniform release profile after a storage for at least three months at 40° C. and 75% relative humidity.Type: ApplicationFiled: July 22, 2009Publication date: February 4, 2010Applicant: GLENMARK GENERICS LTD.Inventors: Kamal Mehta, Sanjay Pandurang Lade, Srinivas G. Arra
-
Publication number: 20100008986Abstract: The present invention relates to the pharmaceutical composition comprising sumatriptan succinate and naproxen sodium, with a proviso that both the active components are in admixture with each other.Type: ApplicationFiled: July 13, 2009Publication date: January 14, 2010Applicant: GLENMARK GENERICS, LTD.Inventors: KAMAL MEHTA, HIDAYTULLA AGA, SANJAY KUMAR SAHU